West Island Brands Past Earnings Performance
Past criteria checks 0/6
West Island Brands's earnings have been declining at an average annual rate of -10.2%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 87.6% per year.
Key information
-10.2%
Earnings growth rate
0.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 87.6% |
| Return on equity | -151.0% |
| Net Margin | -94.1% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How West Island Brands makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 5 | -4 | 2 | 0 |
| 30 Jun 22 | 4 | -5 | 2 | 0 |
| 31 Mar 22 | 3 | -5 | 2 | 0 |
| 31 Dec 21 | 2 | -5 | 2 | 0 |
| 30 Sep 21 | 2 | -10 | 2 | 0 |
| 30 Jun 21 | 1 | -9 | 2 | 0 |
| 31 Mar 21 | 1 | -9 | 2 | 0 |
| 31 Dec 20 | 0 | -8 | 1 | 0 |
| 30 Sep 20 | 0 | -1 | 1 | 0 |
| 30 Jun 20 | 0 | -2 | 1 | 0 |
| 31 Mar 20 | 0 | -2 | 1 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
| 30 Sep 19 | 0 | -4 | 2 | 0 |
| 30 Jun 19 | 0 | -4 | 2 | 0 |
| 31 Mar 19 | 0 | -3 | 3 | 0 |
| 31 Dec 18 | 0 | -5 | 5 | 0 |
| 30 Sep 18 | 0 | -6 | 8 | 0 |
| 30 Jun 18 | 0 | -6 | 8 | 0 |
| 31 Mar 18 | 0 | -6 | 8 | 0 |
| 31 Dec 17 | 0 | -4 | 5 | 0 |
| 30 Sep 17 | 0 | -2 | 2 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 1 | 0 |
| 30 Jun 16 | 0 | -2 | 1 | 0 |
| 31 Mar 16 | 0 | -3 | 1 | 0 |
| 31 Dec 15 | 0 | -3 | 2 | 0 |
| 30 Sep 15 | 0 | -3 | 2 | 0 |
| 30 Jun 15 | 0 | -4 | 2 | 0 |
| 31 Mar 15 | 0 | -3 | 2 | 0 |
| 31 Dec 14 | 0 | -2 | 1 | 0 |
| 30 Sep 14 | 0 | -2 | 1 | 0 |
| 30 Jun 14 | 0 | -1 | 1 | 0 |
| 31 Mar 14 | 0 | -1 | 0 | 0 |
| 31 Dec 13 | 0 | -1 | 1 | 0 |
| 30 Sep 13 | 0 | -1 | 0 | 0 |
| 30 Jun 13 | 0 | -1 | 0 | 0 |
| 31 Mar 13 | 0 | -1 | 0 | 0 |
| 31 Dec 12 | 0 | 0 | 0 | 0 |
Quality Earnings: 39N0 is currently unprofitable.
Growing Profit Margin: 39N0 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 39N0 is unprofitable, and losses have increased over the past 5 years at a rate of 10.2% per year.
Accelerating Growth: Unable to compare 39N0's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 39N0 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 39N0 has a negative Return on Equity (-150.96%), as it is currently unprofitable.